WEBINAR LIVE Molecular analysis and personalized therapy in cancer 6th Edition, July 31, 2020 15:00 - 19:00Find out more navigate_next
The Center for Excellence in Translational Medicine (CEMT), a research core facility of Fundeni Clinical Institute, aims to develop innovation in fundamental, clinical and translational research, by taking a transdisciplinary approach to translational medicine.Read more navigate_next
By bringing together clinicians, multidisciplinary consortia and professional societies, the Center of Excellence in Translational Medicine (CEMT) has all the required components to implement the results of preclinical research in clinical practice. The targeted pathologies are digestive cancers, viral and bacterial infections, metabolic diseases, and liver and digestive tract diseases. CEMT aims to create a European center of excellence in the field of digestive cancer genomics, transplantology, as well as the development of innovative diagostic tools and treatments.
Centred on evaluating new surgical techniques through live interventions on animal models, but also on educational workshops.
Dedicated to improving the early diagnostic techniques in diseases of the upper digestive tract.
Dedicated to the analysis of nucleic acids and proteins in oncological pathologies.
Focused on the prospective analysis of the expression of tissue markers, on a protein level, using immunohistochemistry techniques and Western Blotting.
The strategic goal is to create research cores with advanced technological facilities in the form of research platforms by associating preclinical research laboratories and clinical research centers within the Fundeni Clinical Institute in a unique entity.
The newly created structure provides logistical support for biomedical research through the coordination of studies, quality management, data monitoring, dissemination of good clinical practice, database management and data analysis. Infrastructure is also dedicated to the production of vectors for gene and cellular therapy, as well as for the acquisition of new agents with therapeutic potential in digestive affection.